Flying Eze and its trusted partners need your
permission to store and access cookies, unique identifiers, personal data, and information on your
browsing behaviour on this device. This only applies to Flying Eze. You don’t have to accept, and
you
can change your preferences at any time via the Privacy Options link at the bottom of this screen. If
you don’t accept, you may will still see some personalised ads and content.
Cookies, device identifiers, or other information can be stored or accessed on
your device for the purposes presented to you.
Ads and content can be personalised based on a profile. More data can be added
to better personalise ads and content. Ad and content performance can be
measured. Insights about audiences who saw the ads and content can be derived.
Data can be used to build or improve user experience, systems and software.
Precise geolocation and information about device characteristics can be used.
If you don’t want to accept, please select Read More option below where you can also see how and
why your data may be used. You can also see where we or our partners claim a legitimate interest and
object to the processing of your data.
Australia will continue its COVID-19 inoculation program with AstraZeneca, health officials said on Saturday, after a blood clotting case raised concern about the safety of the vaccine.
A 44-year-old man was admitted to a Melbourne hospital with clotting, days after receiving the AstraZeneca vaccine, suffering serious thrombosis, a condition that prevents normal blood flow through the circulatory system.
The Therapeutic Goods Administration (TGA) regulator and a panel, the Australian Technical Advisory Group on Immunisation (ATAGI), met late Friday and early Saturday to discuss further advice on the AstraZeneca vaccine.
“We have not been advised at this time by ATAGI or the TGA to pause the rollout of the AstraZeneca vaccine in Australia,” Australia’s deputy chief medical officer, Michael Kidd, told a televised briefing Saturday afternoon.
Kidd said, however, that the blood clotting case is “likely” related to the vaccine.
“The risks of serious side effects remain very low, but safety is paramount and that is why TAGI and the TGA are continuing to do due diligence on this case,” Kidd said, adding that further announcements would come next week.
On Thursday, Britain identified 30 cases of rare blood clot events following use of the vaccine. Several nations, including Canada, France, Germany and Spain, limited its use after similar reports.
Possible complications with the rollout of the AstraZeneca vaccine could further slow the already delayed inoculation drive in Australia.
Australia launched mass vaccinations for its 25 million people in February, with most expected to receive the University of Oxford/AstraZeneca vaccine, as 50 million doses are being produced domestically by CSL Ltd.
The country has had troubles, however, rolling out the program, missing a March target by about 3.3 million doses as states and the federal government bickered over the blame.
The troubles follow a year of significant success curbing the virus, with snap lockdowns, border closures and swift tracking limiting coronavirus infections to just under 29,300 infections, with 909 COVID-19 deaths.
On Saturday, Queensland state, the epicenter of the most recent small outbreak of the coronavirus, recorded one new infection, health officials said, but risks to the public were minimal as the victim had been in isolation for days.
(Reporting by Lidia Kelly; Editing by Clarence Fernandez and William Mallard)